Vasopressin as an alternative to norepinephrine in the treatment of milrinone-induced hypotension

Critical Care Medicine

Volumn 28, Issue 1, 2000, Pages 249-252

  Gold, Jeffrey A ^a   Cullinane, Suzanne ^a   Chen, Jonathan ^a   Oz, Mehmet C ^a   Oliver, Juan A ^a   Landry, Donald W ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Hypotension; Milrinone; Norepinephrine; Phosphodiesterase inhibitor; Vasopressin; Vasopressor

Indexed keywords

DOBUTAMINE; DOPAMINE; HYPERTENSIVE AGENT; MILRINONE; NORADRENALIN; PHOSPHODIESTERASE INHIBITOR; VASOPRESSIN;

AGED; ARTERIAL PRESSURE; ARTICLE; CASE REPORT; FEMALE; HUMAN; HYPOTENSION; MALE; PRESSOR RESPONSE; PRIORITY JOURNAL;

EID: 0033968013     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200001000-00043     Document Type: Article

References (20)

1. 1. Mager G, Klocke R: Phosphodiesterase III inhibition or adrenoreceptor stimulation: Milrinone as an alternative to dobutamine in the treatment of severe heart failure. Am Heart J 1991; 121:1974-1983
2. 2. Ludmer PO, Wright RF, Arnold M: Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique. Circulation 1986; 73:130-137
3. 3. Seino Y, Momomura S, Tenako T, et al: Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Crit Care Med 1996; 24: 1490-1497
4. 4. Wagner NH, Brunwald E: The pressor effect of the antidiuretic principle of the posterior pituitary in orthostatic hypotension. J Clin Invest 1956; 35:1412-1418
5. 5. Graybiel A, Glendy RE: Circulatory effects following the intravenous administration of pitressin in normal persons and in patients with hypertension and angina pectoris. Am Heart J 1941; 21:481-489
6. 6. Aisenbrey G, Handelman WA, Arnold P, et al: Vascular effects of arginine vasopressin during fluid deprivation in the rat. J Clin Invest 1981; 67:961-968
7. 7. Schwartz J, Reid IA: Effect of vasopressin blockade on blood pressure regulation during hemorrhage in conscious dogs. Endocrinology 1981; 108:1778-1780
8. 8. Schwartz J, Keil LC, Maselli J, et al: Role of vasopressin in blood pressure regulation during adrenal insufficiency. Endocrinology 1983; 112:234-238
9. 9. Landry DL, Levin HR, Gallant EM, et al: Vasopressin hypersensitivity in vasodilatory shock. Crit Care Med 1997; 25:1279-1282
10. 10. Argenziano M, Choudhri AF, Oz MC, et al: A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997; 96(Suppl II): 286-290
11. m cyclic AMP phosphodiesterase and activation of the cyclic AMP system in vascular smooth muscle by milrinone. J Pharmacol Exp Ther 1988; 247:34-38
12. 12. Lugnier C, Komas N: Modulation of vascular cyclic nucleotide phosphodiesterases by cyclic GMP: Role in vasodilatation. Eur Heart J 1993; 14(Suppl I):141-148
13. 13. Nambi P, Whitman M: Vascular vasopressin receptors mediate inhibition of beta adrenergic receptor-induced cyclic AMP accumulation. J Pharmacol Exp Ther 1986; 237: 143-146
14. 14. Nambi P, Whitman M: Vasopressin-mediated inhibition of atrial natriuretic factor stimulated cGMP accumulation in an established smooth muscle cell line. Proc Natl Acad Sci U S A 1986; 83:8492-8495
15. 15. Vincent JL, Leon M, Berre J, et al: Addition of enoximone to adrenergic agents in the management of severe heart failure. Crit Care Med 1982; 20:1102-1106
16. 16. Uretsky BF, Lawless CE, Verbalis JG, et al: Combined therapy with dobutamine and amrinone in severe heart failure. Chest 1987; 92:657-662
17. 17. Montani J-P, Liard J, Schoun J, et al: Hemodynamic effects of exogenous and endogenous vasopressin at low plasma concentrations in conscious dogs. Circ Res 1980; 47: 346-355
18. 18. Ebert T, Cowley A, Skelton M, et al: Vasopressin reduces cardiac function and augments cardiopulmonary baroreflex resistance increases in man. J Clin Invest 1986; 77: 1136-1142
19. 19. Edwards RM: Segmental effects of norepinephrine and angiotensin II on isolated renal microvessels. Am J Physiol 1983; 244: F526-F534
20. 20. Edwards RM, Trizna W, Hinter LB, et al: Renal microvascular effects of vasopressin and vasopressin antagonist. Am J Physiol 1989; 256:F274-F278